Articles - 2v3d mentioned but not cited (8)
- X-ray and biochemical analysis of N370S mutant human acid β-glucosidase. Wei RR, Hughes H, Boucher S, Bird JJ, Guziewicz N, Van Patten SM, Qiu H, Pan CQ, Edmunds T. J Biol Chem 286 299-308 (2011)
- Identification of pharmacological chaperones for Gaucher disease and characterization of their effects on beta-glucocerebrosidase by hydrogen/deuterium exchange mass spectrometry. Tropak MB, Kornhaber GJ, Rigat BA, Maegawa GH, Buttner JD, Blanchard JE, Murphy C, Tuske SJ, Coales SJ, Hamuro Y, Brown ED, Mahuran DJ. Chembiochem 9 2650-2662 (2008)
- A Bacteroidetes locus dedicated to fungal 1,6-β-glucan degradation: Unique substrate conformation drives specificity of the key endo-1,6-β-glucanase. Temple MJ, Cuskin F, Baslé A, Hickey N, Speciale G, Williams SJ, Gilbert HJ, Lowe EC. J Biol Chem 292 10639-10650 (2017)
- Molecular basis of reduced glucosylceramidase activity in the most common Gaucher disease mutant, N370S. Offman MN, Krol M, Silman I, Sussman JL, Futerman AH. J Biol Chem 285 42105-42114 (2010)
- A Guided Tour of the Structural Biology of Gaucher Disease: Acid-β-Glucosidase and Saposin C. Lieberman RL. Enzyme Res 2011 973231 (2011)
- Human glucocerebrosidase mediates formation of xylosyl-cholesterol by β-xylosidase and transxylosidase reactions. Boer DE, Mirzaian M, Ferraz MJ, Zwiers KC, Baks MV, Hazeu MD, Ottenhoff R, Marques ARA, Meijer R, Roos JCP, Cox TM, Boot RG, Pannu N, Overkleeft HS, Artola M, Aerts JM. J Lipid Res 62 100018 (2021)
- Protein structural features predict responsiveness to pharmacological chaperone treatment for three lysosomal storage disorders. Woodard J, Zheng W, Zhang Y. PLoS Comput Biol 17 e1009370 (2021)
- Selective Targeting of the Interconversion between Glucosylceramide and Ceramide by Scaffold Tailoring of Iminosugar Inhibitors. Baudoin-Dehoux C, Castellan T, Rodriguez F, Rives A, Stauffert F, Garcia V, Levade T, Compain P, Génisson Y. Molecules 24 E354 (2019)
Reviews citing this publication (18)
- Mechanistic insights into glycosidase chemistry. Vocadlo DJ, Davies GJ. Curr Opin Chem Biol 12 539-555 (2008)
- Glycosphingolipids--nature, function, and pharmacological modulation. Wennekes T, van den Berg RJ, Boot RG, van der Marel GA, Overkleeft HS, Aerts JM. Angew Chem Int Ed Engl 48 8848-8869 (2009)
- Covalent inhibitors of glycosidases and their applications in biochemistry and biology. Rempel BP, Withers SG. Glycobiology 18 570-586 (2008)
- Less Is More: Substrate Reduction Therapy for Lysosomal Storage Disorders. Coutinho MF, Santos JI, Alves S. Int J Mol Sci 17 E1065 (2016)
- Acid beta-glucosidase: insights from structural analysis and relevance to Gaucher disease therapy. Kacher Y, Brumshtein B, Boldin-Adamsky S, Toker L, Shainskaya A, Silman I, Sussman JL, Futerman AH. Biol Chem 389 1361-1369 (2008)
- Tuning protein folding in lysosomal storage diseases: the chemistry behind pharmacological chaperones. Pereira DM, Valentão P, Andrade PB. Chem Sci 9 1740-1752 (2018)
- Molecular pharming's foot in the FDA's door: Protalix's trailblazing story. Mor TS. Biotechnol Lett 37 2147-2150 (2015)
- Pharmacological chaperone therapy for lysosomal storage diseases. Parenti G, Moracci M, Fecarotta S, Andria G. Future Med Chem 6 1031-1045 (2014)
- The development and use of small molecule inhibitors of glycosphingolipid metabolism for lysosomal storage diseases. Shayman JA, Larsen SD. J Lipid Res 55 1215-1225 (2014)
- Disease-associated carbohydrate-recognising proteins and structure-based inhibitor design. von Itzstein M. Curr Opin Struct Biol 18 558-566 (2008)
- Glucocerebrosidase: Functions in and Beyond the Lysosome. Boer DEC, van Smeden J, Bouwstra JA, Aerts JMFG. J Clin Med 9 E736 (2020)
- Gaucher disease: Basic and translational science needs for more complete therapy and management. Grabowski GA, Antommaria AHM, Kolodny EH, Mistry PK. Mol Genet Metab 132 59-75 (2021)
- The metabolism of glucocerebrosides - From 1965 to the present. Futerman AH, Platt FM. Mol Genet Metab 120 22-26 (2017)
- Pharmacoperone drugs: targeting misfolded proteins causing lysosomal storage-, ion channels-, and G protein-coupled receptors-associated conformational disorders. Hou ZS, Ulloa-Aguirre A, Tao YX. Expert Rev Clin Pharmacol 11 611-624 (2018)
- Biological activities of 3,4,5-trihydroxypiperidines and their N- and O-derivatives. Prichard K, Campkin D, O'Brien N, Kato A, Fleet GWJ, Simone MI. Chem Biol Drug Des 92 1171-1197 (2018)
- Approaches for probing and evaluating mammalian sphingolipid metabolism. Snider JM, Luberto C, Hannun YA. Anal Biochem 575 70-86 (2019)
- New therapeutic approaches for Krabbe disease: The potential of pharmacological chaperones. Spratley SJ, Deane JE. J Neurosci Res 94 1203-1219 (2016)
- GCase Enhancers: A Potential Therapeutic Option for Gaucher Disease and Other Neurological Disorders. Martínez-Bailén M, Clemente F, Matassini C, Cardona F. Pharmaceuticals (Basel) 15 823 (2022)
Articles citing this publication (44)
- Ultrasensitive in situ visualization of active glucocerebrosidase molecules. Witte MD, Kallemeijn WW, Aten J, Li KY, Strijland A, Donker-Koopman WE, van den Nieuwendijk AM, Bleijlevens B, Kramer G, Florea BI, Hooibrink B, Hollak CE, Ottenhoff R, Boot RG, van der Marel GA, Overkleeft HS, Aerts JM. Nat Chem Biol 6 907-913 (2010)
- ELIGLUSTAT TARTRATE: Glucosylceramide Synthase Inhibitor Treatment of Type 1 Gaucher Disease. Shayman JA. Drugs Future 35 613-620 (2010)
- Glycomimetic-based pharmacological chaperones for lysosomal storage disorders: lessons from Gaucher, GM1-gangliosidosis and Fabry diseases. Sánchez-Fernández EM, García Fernández JM, Mellet CO. Chem Commun (Camb) 52 5497-5515 (2016)
- Glycosylation and functionality of recombinant β-glucocerebrosidase from various production systems. Tekoah Y, Tzaban S, Kizhner T, Hainrichson M, Gantman A, Golembo M, Aviezer D, Shaaltiel Y. Biosci Rep 33 e00071 (2013)
- Synthesis and biological characterisation of novel N-alkyl-deoxynojirimycin alpha-glucosidase inhibitors. Rawlings AJ, Lomas H, Pilling AW, Lee MJ, Alonzi DS, Rountree JS, Jenkinson SF, Fleet GW, Dwek RA, Jones JH, Butters TD. Chembiochem 10 1101-1105 (2009)
- First pilot newborn screening for four lysosomal storage diseases in an Italian region: identification and analysis of a putative causative mutation in the GBA gene. Paciotti S, Persichetti E, Pagliardini S, Deganuto M, Rosano C, Balducci C, Codini M, Filocamo M, Menghini AR, Pagliardini V, Pasqui S, Bembi B, Dardis A, Beccari T. Clin Chim Acta 413 1827-1831 (2012)
- 6-Amino-6-deoxy-5,6-di-N-(N'-octyliminomethylidene)nojirimycin: synthesis, biological evaluation, and crystal structure in complex with acid beta-glucosidase. Brumshtein B, Aguilar-Moncayo M, García-Moreno MI, Ortiz Mellet C, García Fernández JM, Silman I, Shaaltiel Y, Aviezer D, Sussman JL, Futerman AH. Chembiochem 10 1480-1485 (2009)
- Design, synthesis, and biological evaluation of N-alkylated deoxynojirimycin (DNJ) derivatives for the treatment of dengue virus infection. Yu W, Gill T, Wang L, Du Y, Ye H, Qu X, Guo JT, Cuconati A, Zhao K, Block TM, Xu X, Chang J. J Med Chem 55 6061-6075 (2012)
- Azasugar inhibitors as pharmacological chaperones for Krabbe disease. Hill CH, Viuff AH, Spratley SJ, Salamone S, Christensen SH, Read RJ, Moriarty NW, Jensen HH, Deane JE. Chem Sci 6 3075-3086 (2015)
- Comparative therapeutic effects of velaglucerase alfa and imiglucerase in a Gaucher disease mouse model. Xu YH, Sun Y, Barnes S, Grabowski GA. PLoS One 5 e10750 (2010)
- Structural snapshots illustrate the catalytic cycle of β-galactocerebrosidase, the defective enzyme in Krabbe disease. Hill CH, Graham SC, Read RJ, Deane JE. Proc Natl Acad Sci U S A 110 20479-20484 (2013)
- Promising results of the chaperone effect caused by imino sugars and aminocyclitol derivatives on mutant glucocerebrosidases causing Gaucher disease. Sánchez-Ollé G, Duque J, Egido-Gabás M, Casas J, Lluch M, Chabás A, Grinberg D, Vilageliu L. Blood Cells Mol Dis 42 159-166 (2009)
- Pharmacological chaperones for human α-N-acetylgalactosaminidase. Clark NE, Metcalf MC, Best D, Fleet GW, Garman SC. Proc Natl Acad Sci U S A 109 17400-17405 (2012)
- β-Glucuronidase from Lactobacillus brevis useful for baicalin hydrolysis belongs to glycoside hydrolase family 30. Sakurama H, Kishino S, Uchibori Y, Yonejima Y, Ashida H, Kita K, Takahashi S, Ogawa J. Appl Microbiol Biotechnol 98 4021-4032 (2014)
- Cyclodextrin-mediated crystallization of acid β-glucosidase in complex with amphiphilic bicyclic nojirimycin analogues. Brumshtein B, Aguilar-Moncayo M, Benito JM, García Fernandez JM, Silman I, Shaaltiel Y, Aviezer D, Sussman JL, Futerman AH, Ortiz Mellet C. Org Biomol Chem 9 4160-4167 (2011)
- Molecular basis for beta-glucosidase inhibition by ring-modified calystegine analogues. Aguilar M, Gloster TM, García-Moreno MI, Ortiz Mellet C, Davies GJ, Llebaria A, Casas J, Egido-Gabás M, García Fernandez JM. Chembiochem 9 2612-2618 (2008)
- Binding of 3,4,5,6-tetrahydroxyazepanes to the acid-β-glucosidase active site: implications for pharmacological chaperone design for Gaucher disease. Orwig SD, Tan YL, Grimster NP, Yu Z, Powers ET, Kelly JW, Lieberman RL. Biochemistry 50 10647-10657 (2011)
- GC/MS Analysis of Essential Oil and Enzyme Inhibitory Activities of Syzygium cumini (Pamposia) Grown in Egypt: Chemical Characterization and Molecular Docking Studies. El-Nashar HAS, Eldehna WM, Al-Rashood ST, Alharbi A, Eskandrani RO, Aly SH. Molecules 26 6984 (2021)
- Crystal structure of the Salmonella enterica serovar typhimurium virulence factor SrfJ, a glycoside hydrolase family enzyme. Kim YG, Kim JH, Kim KJ. J Bacteriol 191 6550-6554 (2009)
- Ethylenedioxy-PIP2 oxalate reduces ganglioside storage in juvenile Sandhoff disease mice. Arthur JR, Wilson MW, Larsen SD, Rockwell HE, Shayman JA, Seyfried TN. Neurochem Res 38 866-875 (2013)
- Nanomolar affinity, iminosugar-based chemical probes for specific labeling of lysosomal glucocerebrosidase. van Scherpenzeel M, van den Berg RJ, Donker-Koopman WE, Liskamp RM, Aerts JM, Overkleeft HS, Pieters RJ. Bioorg Med Chem 18 267-273 (2010)
- Rapid modifications of N-substitution in iminosugars: development of new β-glucocerebrosidase inhibitors and pharmacological chaperones for Gaucher disease. Cheng WC, Weng CY, Yun WY, Chang SY, Lin YC, Tsai FJ, Huang FY, Chen YR. Bioorg Med Chem 21 5021-5028 (2013)
- Stabilization of Glucocerebrosidase by Active Site Occupancy. Ben Bdira F, Kallemeijn WW, Oussoren SV, Scheij S, Bleijlevens B, Florea BI, van Roomen CPAA, Ottenhoff R, van Kooten MJFM, Walvoort MTC, Witte MD, Boot RG, Ubbink M, Overkleeft HS, Aerts JMFG. ACS Chem Biol 12 1830-1841 (2017)
- Synthesis of N-substituted ε-hexonolactams as pharmacological chaperones for the treatment of N370S mutant Gaucher disease. Wang GN, Twigg G, Butters TD, Zhang S, Zhang L, Zhang LH, Ye XS. Org Biomol Chem 10 2923-2927 (2012)
- Twelve years of experience with miglustat in the treatment of type 1 Gaucher disease: The Spanish ZAGAL project. Giraldo P, Andrade-Campos M, Alfonso P, Irun P, Atutxa K, Acedo A, Barez A, Blanes M, Diaz-Morant V, Fernández-Galán MA, Franco R, Gil-Cortes C, Giner V, Ibañez A, Latre P, Loyola I, Luño E, Hernández-Martin R, Medrano-Engay B, Puerta J, Roig I, de la Serna J, Salamero O, Villalón L, Pocovi M. Blood Cells Mol Dis 68 173-179 (2018)
- In vitro studies of novel PRKAR1A mutants that extend the predicted RIα protein sequence into the 3'-untranslated open reading frame: proteasomal degradation leads to RIα haploinsufficiency and Carney complex. Patronas Y, Horvath A, Greene E, Tsang K, Bimpaki E, Haran M, Nesterova M, Stratakis CA. J Clin Endocrinol Metab 97 E496-502 (2012)
- Bicyclic isoureas derived from 1-deoxynojirimycin are potent inhibitors of β-glucocerebrosidase. Sevšek A, Čelan M, Erjavec B, Quarles van Ufford L, Sastre Toraño J, Moret EE, Pieters RJ, Martin NI. Org Biomol Chem 14 8670-8673 (2016)
- New insights into the pharmacological chaperone activity of c2-substituted glucoimidazoles for the treatment of Gaucher disease. Li Z, Li T, Dai S, Xie X, Ma X, Zhao W, Zhang W, Li J, Wang PG. Chembiochem 14 1239-1247 (2013)
- Novel easily accessible glucosidase inhibitors: 4-hydroxy-5-alkoxy-1,2-cyclohexanedicarboxylic acids. Brazdova B, Tan NS, Samoshina NM, Samoshin VV. Carbohydr Res 344 311-321 (2009)
- Participation of asparagine 370 and glutamine 235 in the catalysis by acid beta-glucosidase: the enzyme deficient in Gaucher disease. Liou B, Grabowski GA. Mol Genet Metab 97 65-74 (2009)
- Synthetic deoxynojirimycin derivatives bearing a thiolated, fluorinated or unsaturated N-alkyl chain: identification of potent α-glucosidase and trehalase inhibitors as well as F508del-CFTR correctors. Cendret V, Legigan T, Mingot A, Thibaudeau S, Adachi I, Forcella M, Parenti P, Bertrand J, Becq F, Norez C, Désiré J, Kato A, Blériot Y. Org Biomol Chem 13 10734-10744 (2015)
- Comparison of a molecular dynamics model with the X-ray structure of the N370S acid-beta-glucosidase mutant that causes Gaucher disease. Offman MN, Krol M, Rost B, Silman I, Sussman JL, Futerman AH. Protein Eng Des Sel 24 773-775 (2011)
- Accessing 2-substituted piperidine iminosugars by organometallic addition/intramolecular reductive amination: aldehyde vs. nitrone route. Mirabella S, Fibbi G, Matassini C, Faggi C, Goti A, Cardona F. Org Biomol Chem 15 9121-9126 (2017)
- Glycosylation is crucial for a proper catalytic site organization in human glucocerebrosidase. Pol-Fachin L, Siebert M, Verli H, Saraiva-Pereira ML. Glycoconj J 33 237-244 (2016)
- Synthesis and characterization of novel, conjugated, fluorescent DNJ derivatives for α-glucosidase recognition. Hatano A, Kanno Y, Kondo Y, Sunaga Y, Umezawa H, Okada M, Yamada H, Iwaki R, Kato A, Fukui K. Bioorg Med Chem 25 773-778 (2017)
- Distinguishing the differences in β-glycosylceramidase folds, dynamics, and actions informs therapeutic uses. Ben Bdira F, Artola M, Overkleeft HS, Ubbink M, Aerts JMFG, Aerts JMFG. J Lipid Res 59 2262-2276 (2018)
- Selective chaperone effect of aminocyclitol derivatives on G202R and other mutant glucocerebrosidases causing Gaucher disease. Serra-Vinardell J, Díaz L, Gutiérrez-de Terán H, Sánchez-Ollé G, Bujons J, Michelakakis H, Mavridou I, Aerts JM, Delgado A, Grinberg D, Vilageliu L, Casas J. Int J Biochem Cell Biol 54 245-254 (2014)
- Tuning the activity of iminosugars: novel N-alkylated deoxynojirimycin derivatives as strong BuChE inhibitors. Ahuja-Casarín AI, Merino-Montiel P, Vega-Baez JL, Montiel-Smith S, Fernandes MX, Lagunes I, Maya I, Padrón JM, López Ó, Fernández-Bolaños JG. J Enzyme Inhib Med Chem 36 138-146 (2021)
- Design, Synthesis and Structural Analysis of Glucocerebrosidase Imaging Agents. Rowland RJ, Chen Y, Breen I, Wu L, Offen WA, Beenakker TJ, Su Q, van den Nieuwendijk AMCH, Aerts JMFG, Artola M, Overkleeft HS, Davies GJ. Chemistry 27 16377-16388 (2021)
- Investigation of novel pharmacological chaperones for Gaucher Disease. Yilmazer B, Yagci ZB, Bakar E, Ozden B, Ulgen K, Ozkirimli E. J Mol Graph Model 76 364-378 (2017)
- Orthoester functionalized N-guanidino derivatives of 1,5-dideoxy-1,5-imino-d-xylitol as pH-responsive inhibitors of β-glucocerebrosidase. Sevšek A, Sastre Toraño J, Quarles van Ufford L, Moret EE, Pieters RJ, Martin NI. Medchemcomm 8 2050-2054 (2017)
- Selective α-glucosidase substrates and inhibitors containing short aromatic peptidyl moieties. Park S, Hyun S, Do SI, Yu J. Bioorg Med Chem Lett 21 2441-2444 (2011)
- Fluorinated hydroxypiperidines as selective β-glucosidase inhibitors. Le Guen C, Mena-Barragán T, Ortiz Mellet C, Gueyrard D, Pfund E, Lequeux T. Org Biomol Chem 13 5983-5996 (2015)
- Mass spectrometric study of gas-phase ions of acid β-glucosidase (Cerezyme) and iminosugar pharmacological chaperones. Rajabi K. J Mass Spectrom 49 1002-1009 (2014)